rdf:type |
|
lifeskim:mentions |
|
pubmed:issue |
14
|
pubmed:dateCreated |
1996-9-20
|
pubmed:abstractText |
A model system has been developed to explore the relationship between cell cycle arrest and chemotherapeutic toxicity. An isopropyl-1-thio-beta-D-galactopyranoside-inducible P16 construct was introduced stably into a melanoma cell line and used to promote G0-G1 arrest in the recipient cells. The state of arrest was reversible and did not compromise cell viability over a period of at least 7 days. Isopropyl-1-thio-beta-D-galactopyranoside-treated, arrested cells were significantly more resistant to the chemotherapeutic agents methotrexate (approximately 50 times), vinblastine (>100 times), and cisplatin (approximately 10 times) compared to controls. This strategy of protection from chemotherapy exploits one of the basic genotypic differences between normal cells and tumor cells: the integrity of genetic pathways that regulate growth.
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jul
|
pubmed:issn |
0008-5472
|
pubmed:author |
|
pubmed:issnType |
Print
|
pubmed:day |
15
|
pubmed:volume |
56
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
3199-202
|
pubmed:dateRevised |
2005-11-17
|
pubmed:meshHeading |
pubmed-meshheading:8764106-Antineoplastic Agents,
pubmed-meshheading:8764106-Carrier Proteins,
pubmed-meshheading:8764106-Cell Cycle,
pubmed-meshheading:8764106-Cisplatin,
pubmed-meshheading:8764106-Cyclin-Dependent Kinase Inhibitor p16,
pubmed-meshheading:8764106-Drug Administration Schedule,
pubmed-meshheading:8764106-Humans,
pubmed-meshheading:8764106-Methotrexate,
pubmed-meshheading:8764106-Tumor Cells, Cultured,
pubmed-meshheading:8764106-Vinblastine
|
pubmed:year |
1996
|
pubmed:articleTitle |
Reversible, p16-mediated cell cycle arrest as protection from chemotherapy.
|
pubmed:affiliation |
Myriad Genetics, Inc., Salt Lake City, Utah 84108, USA.
|
pubmed:publicationType |
Journal Article
|